Published in Cancer Res on November 15, 2003
The Ras-association domain family (RASSF) members and their role in human tumourigenesis. Biochim Biophys Acta (2007) 2.82
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res (2013) 1.92
DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res (2011) 1.85
Detection of β cell death in diabetes using differentially methylated circulating DNA. Proc Natl Acad Sci U S A (2011) 1.77
Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res (2010) 1.46
Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter. Mol Cell Biol (2005) 1.45
Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol (2009) 1.41
DNA methylation based biomarkers in non-invasive cancer screening. Curr Mol Med (2010) 1.32
The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci (2013) 1.25
Epigenomics and breast cancer. Pharmacogenomics (2008) 1.23
Hypermethylation of tumor suppressor genes involved in critical regulatory pathways for developing a blood-based test in breast cancer. PLoS One (2011) 1.21
Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res (2014) 1.19
DNA methylation in peripheral blood: a potential biomarker for cancer molecular epidemiology. J Epidemiol (2012) 1.19
Promoter methylation and the detection of breast cancer. Cancer Causes Control (2009) 1.18
Beyond genetics: epigenetic code in chronic kidney disease. Kidney Int (2010) 1.18
The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer (2009) 1.09
The prognostic role of RASSF1A promoter methylation in breast cancer: a meta-analysis of published data. PLoS One (2012) 1.08
Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer (2007) 1.06
Pan-cancer patterns of DNA methylation. Genome Med (2014) 1.02
SFRP2 methylation in fecal DNA--a marker for colorectal polyps. Int J Colorectal Dis (2007) 1.02
Epigenetic regulation in estrogen receptor positive breast cancer--role in treatment response. J Mammary Gland Biol Neoplasia (2010) 1.02
Quantitative analysis and diagnostic significance of methylated SLC19A3 DNA in the plasma of breast and gastric cancer patients. PLoS One (2011) 1.01
Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer (2005) 1.01
DNA methylation in pre-diagnostic serum samples of breast cancer cases: results of a nested case-control study. Cancer Epidemiol (2010) 0.98
Gene promoter methylation is associated with increased mortality among women with breast cancer. Breast Cancer Res Treat (2009) 0.97
Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur J Med Res (2010) 0.96
Aberrant methylation of the Adenomatous Polyposis Coli (APC) gene promoter is associated with the inflammatory breast cancer phenotype. Br J Cancer (2008) 0.95
A new method for gene discovery in large-scale microarray data. Nucleic Acids Res (2006) 0.95
DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomark Insights (2008) 0.95
CpG methylation analysis--current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn (2009) 0.94
Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res (2013) 0.94
RASSF1A hypermethylation in pretreatment serum DNA of neuroblastoma patients: a prognostic marker. Br J Cancer (2009) 0.93
Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci (2010) 0.92
TIMP3 and CCNA1 hypermethylation in HNSCC is associated with an increased incidence of second primary tumors. J Transl Med (2013) 0.92
Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer. BMC Cancer (2014) 0.92
Aberrant promoter CpG methylation and its translational applications in breast cancer. Chin J Cancer (2011) 0.90
Sox17 promoter methylation in plasma DNA is associated with poor survival and can be used as a prognostic factor in breast cancer. Medicine (Baltimore) (2015) 0.88
Comparison of methylation profiling in cancerous and their corresponding normal tissues from korean patients with breast cancer. Ann Lab Med (2013) 0.87
Detection of aberrant methylation of a six-gene panel in serum DNA for diagnosis of breast cancer. Oncotarget (2016) 0.86
Epigenetic Signatures in Breast Cancer: Clinical Perspective. Breast Care (Basel) (2010) 0.86
Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer-testis (CT-X) antigens. BMC Cancer (2013) 0.86
Lower ADD1 gene promoter DNA methylation increases the risk of essential hypertension. PLoS One (2013) 0.86
Whole blood DNA aberrant methylation in pancreatic adenocarcinoma shows association with the course of the disease: a pilot study. PLoS One (2012) 0.85
Aberrant methylation of RASSF1A in plasma DNA before breast cancer diagnosis in the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev (2009) 0.85
Unraveling breast cancer heterogeneity through transcriptomic and epigenomic analysis. Ann Surg Oncol (2009) 0.85
Novel multiplex MethyLight protocol for detection of DNA methylation in patient tissues and bodily fluids. Sci Rep (2014) 0.84
Differential peripheral blood gene expression profile based on Her2 expression on primary tumors of breast cancer patients. PLoS One (2014) 0.83
A new dimethyl sulfoxide-based method for gene promoter methylation detection. J Mol Diagn (2007) 0.82
Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. Breast Cancer Res (2014) 0.82
ESR1 gene promoter region methylation in free circulating DNA and its correlation with estrogen receptor protein expression in tumor tissue in breast cancer patients. BMC Cancer (2014) 0.82
Whole-genome bisulfite sequencing of cell-free DNA identifies signature associated with metastatic breast cancer. Clin Epigenetics (2015) 0.82
Microtubule segment stabilization by RASSF1A is required for proper microtubule dynamics and Golgi integrity. Mol Biol Cell (2014) 0.81
Quantitative gene analysis of methylation and expression (Q-GAME) in fresh or fixed cells and tissues. Exp Dermatol (2014) 0.81
Epigenetics in diagnosis, prognostic assessment and treatment of cancer: an update. EXCLI J (2014) 0.81
Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis. PLoS One (2016) 0.81
Methylated DNA and high total DNA levels in the serum of patients with breast cancer following neoadjuvant chemotherapy are predictive of a poor prognosis. Oncol Lett (2014) 0.80
Promoter Hypermethylation in White Blood Cell DNA and Breast Cancer Risk. J Cancer (2015) 0.80
High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance. PLoS One (2010) 0.80
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients. Biomed Res Int (2014) 0.79
Methyl-binding domain protein-based DNA isolation from human blood serum combines DNA analyses and serum-autoantibody testing. BMC Clin Pathol (2011) 0.79
Breast Cancer Biomarkers: Utility in Clinical Practice. Curr Breast Cancer Rep (2013) 0.78
Zeranol down-regulates p53 expression in primary cultured human breast cancer epithelial cells through epigenetic modification. Int J Mol Sci (2011) 0.78
Concordance of Hypermethylated DNA and the Tumor Markers CA 15-3, CEA, and TPA in Serum during Monitoring of Patients with Advanced Breast Cancer. Biomed Res Int (2015) 0.77
Aberrant DNA methylation of ESR1 and p14ARF genes could be useful as prognostic indicators in osteosarcoma. Onco Targets Ther (2013) 0.77
Epigenetic Biomarkers of Breast Cancer Risk: Across the Breast Cancer Prevention Continuum. Adv Exp Med Biol (2016) 0.77
DNA Methylation Patterns Can Estimate Nonequivalent Outcomes of Breast Cancer with the Same Receptor Subtypes. PLoS One (2015) 0.77
Methylation biomarkers for pleomorphic lobular breast cancer - a short report. Cell Oncol (Dordr) (2015) 0.77
Pyrosequencing quantified methylation level of BRCA1 promoter as prognostic factor for survival in breast cancer patient. Oncotarget (2016) 0.76
Quantitative assessment of the association between APC promoter methylation and breast cancer. Oncotarget (2016) 0.76
Association between aberrant APC promoter methylation and breast cancer pathogenesis: a meta-analysis of 35 observational studies. PeerJ (2016) 0.76
Gene promoter hypermethylation in tumors and plasma of breast cancer patients. Cancer Res Treat (2005) 0.75
Delineating the effect of demethylating agent 5-aza-2'-deoxycytidine on human Caco-2 colonic carcinoma cells. Oncol Lett (2016) 0.75
Promoter methylation of TRIM9 as a marker for detection of circulating tumor DNA in breast cancer patients. Springerplus (2015) 0.75
Acetylation targets HSD17B4 for degradation via the CMA pathway in response to estrone. Autophagy (2017) 0.75
Epigenetic regulation of APC in the molecular pathogenesis of gallbladder cancer. Indian J Med Res (2016) 0.75
Value of circulating cell-free DNA analysis as a diagnostic tool for breast cancer: a meta-analysis. Oncotarget (2017) 0.75
Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene Polymorphism rs1989839 is Associated with Risk and Metastatic Potential of Osteosarcoma in Young Chinese Individuals: A Multi-Center, Case-Control Study. Med Sci Monit (2016) 0.75
Impact of RASSF1A gene methylation on the metastatic axillary nodal status in breast cancer patients. Oncol Lett (2017) 0.75
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet (2006) 13.63
Epigenetic stem cell signature in cancer. Nat Genet (2006) 9.62
A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med (2005) 6.86
Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res (2010) 6.03
The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res (2005) 4.02
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010) 4.01
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res (2007) 3.79
An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One (2009) 3.33
Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res (2004) 3.23
Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol (2010) 2.91
Independent surrogate variable analysis to deconvolve confounding factors in large-scale microarray profiling studies. Bioinformatics (2011) 2.91
The natural history of multiple system atrophy: a prospective European cohort study. Lancet Neurol (2013) 2.65
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol (2008) 2.28
2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer (2011) 2.24
Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology (2014) 2.02
Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res (2006) 1.99
HPV antibody detection by ELISA with capsid protein L1 fused to glutathione S-transferase. J Virol Methods (2002) 1.97
Visualization and characterization of migratory Langerhans cells in murine skin and lymph nodes by antibodies against Langerin/CD207. J Invest Dermatol (2003) 1.93
Circulating tumor cells in metastatic breast cancer--toward individualized treatment? N Engl J Med (2004) 1.89
A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer (2006) 1.82
Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet (2004) 1.80
Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008) 1.75
DNA hypomethylation and ovarian cancer biology. Cancer Res (2004) 1.75
Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium HumanMethylation27 BeadChip. Methods (2010) 1.71
Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. Breast Cancer Res Treat (2011) 1.71
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an independent prognostic marker for reduced survival of patients with epithelial ovarian cancer. Gynecol Oncol (2006) 1.69
Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Med (2012) 1.65
Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res (2005) 1.62
Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res (2008) 1.60
Diagnostic accuracy of guided cervical biopsies: a prospective multicenter study comparing the histopathology of simultaneous biopsy and cone specimen. Am J Obstet Gynecol (2010) 1.60
Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene (2002) 1.59
DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther (2004) 1.53
Interference of the new oral anticoagulant dabigatran with frequently used coagulation tests. Clin Chem Lab Med (2012) 1.53
Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics (2012) 1.51
Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res (2004) 1.45
Detection of human papillomavirus DNA in breast cancer of patients with cervical cancer history. J Clin Virol (2004) 1.45
HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer. Int J Cancer (2008) 1.44
Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF. Cancer Biol Ther (2006) 1.44
International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiat Oncol Biol Phys (2010) 1.44
Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients. Clin Cancer Res (2007) 1.40
L1CAM in early-stage type I endometrial cancer: results of a large multicenter evaluation. J Natl Cancer Inst (2013) 1.40
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 1.36
Prognostic significance of signal transducer and activator of transcription 1 activation in breast cancer. Clin Cancer Res (2002) 1.34
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer. PLoS Genet (2012) 1.33
Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial. J Clin Oncol (2011) 1.31
Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol (2003) 1.31
A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. BMC Bioinformatics (2012) 1.26
Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol (2010) 1.20
ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma. Neuroradiology (2010) 1.20
Plasma fibrinogen levels and prognosis in patients with ovarian cancer: a multicenter study. Oncologist (2009) 1.19
Dysregulated monocyte iron homeostasis and erythropoietin formation in patients with anemia of chronic disease. Blood (2006) 1.18
Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol (2010) 1.18
Role of miR-34a as a suppressor of L1CAM in endometrial carcinoma. Oncotarget (2014) 1.18
Cellular network entropy as the energy potential in Waddington's differentiation landscape. Sci Rep (2013) 1.12
Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins. Proc Natl Acad Sci U S A (2011) 1.11
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development. PLoS Med (2013) 1.10
Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain (2005) 1.09
Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry. Psychiatry Res (2008) 1.08
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissue. Cancer Lett (2006) 1.07
DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res (2004) 1.06
Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci (2004) 1.06
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer (2016) 1.06
Conservative management of abnormally invasive placenta: four case reports. Acta Obstet Gynecol Scand (2013) 1.06
Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci (2006) 1.06
Methylated DNA as a possible screening marker for neoplastic disease in several body fluids. Expert Rev Mol Diagn (2003) 1.06
Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol (2004) 1.06
Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res (2005) 1.05